Skip NavigationSkip to Content
Return Return to Search Results

Innovative Technologies for Advancement of WHO Risk Group 4 Pathogens Research

  1. Author:
    Logue, James
    Solomon,Jeffrey
    Niemeyer, Brian F.
    Benam, Kambez H.
    Lin, Aaron E.
    Bjornson, Zach
    Jiang, Sizun
    McIlwain, David R.
    Nolan, Garry P.
    Palacios, Gustavo
    Kuhn, Jens H.

  2. Author Address

    NIAID, Integrated Res Facil Ft Detrick, NIH, Frederick, MD 21702 USA.NIAID, Integrated Res Facil Ft Detrick IRF Frederick, Div Clin Res DCR, NIH, Frederick, MD 21702 USA.NCI, Integrated Res Facil Ft Detrick, Clin Monitoring Res Program Directorate, Frederick Natl Lab Canc Res, Frederick, MD 21701 USA.Univ Colorado, Dept Med, Div Pulm Sci & Crit Care Med, Anschutz Med Campus, Aurora, CO USA.Univ Colorado Denver, Dept Bioengn, Aurora, CO USA.Harvard Med Sch, Harvard Program Virol, Boston, MA 02115 USA.Harvard Univ, FAS Ctr Syst Biol, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA.Broad Inst Harvard & MIT, Cambridge, MA USA.Stanford Univ, Sch Med, Dept Microbiol & Immunol, Baxter Lab Stem Cell Biol, Stanford, CA 94305 USA.US Army Med Res Inst Infect Dis, Frederick, MD USA.
    1. Year: 2019
  2. SPRINGER INTERNATIONAL PUBLISHING AG,
    1. Number of Pages: 437-469
  4. ISBN: 978-3-030-29021-4
  1. Abstract:

    Risk Group 4 pathogens are a group of often lethal human viruses for which there are no widely available vaccines or therapeutics. These viruses are endemic to specific geographic locations and typically cause relatively infrequent, self-limiting, but often devastating human disease outbreaks (e.g. Ebola virus, Kyasanur Forest disease virus, Lassa virus). The overall rarity of disease outbreaks with the associated lack of clinical data and the requirement for research on Risk Group 4 pathogens to be performed in maximum (biosafety level 4) containment necessarily impede progress in medical countermeasure development. Next-generation technologies may aid to bridge the current gaps of knowledge by increasing the amount of useful data that can be gleaned from individual diagnostic samples, possibly even at point-of-care; enable personalized medicine approaches through genomic virus characterization in the clinic; refine our comprehension of pathogenesis by using ex vivo technologies such as organs-on-chips or organoids; identify novel correlates of protection or disease survival that could inform novel medical countermeasure development; or support patient and treatment response monitoring through non-invasive techniques such as medical imaging. This chapter provides an overview of a subset of such technologies and how they may positively impact the field of Risk Group 4 pathogen research in the near future.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1007/978-3-030-29022-1_15
  3. View record in Web of Science®
  4. WOS: 000572052700017

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel